Clinical trials: Treatment With Proton Beam Radiation Therapy
- Condition Treatment With Proton Beam Radiation Therapy
- Funder type Industry (pharma, biotech, devices)
Heartburn
Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment
The purpose of this pilot study is to investigate the association between gastric acid suppression and relief of 24 hour heartburn following treatment with the proton pump inhibitor (PPI) drug esomeprazole in frequent heartburn…
- Trial name
- NCT02708355
- Testing
- Esomeprazole 20 mg
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Pfizer
Dyspepsia, H. Pylori Infection
Supplementation With L. Reuteri in H. Pylori Infected Adults
To determine whether simultaneous use of L. reuteri ProGastria and proton pump inhibitors can eradicate H. pylori in humans in the absence of antibiotics.
- Trial name
- NCT01449500
- Testing
- L. reuteri
- Where
- Slovakia
- Volunteers
- 56 people
- Sponsor
- Lama Medical Care s.r.o.
Solid Tumor, Adult
Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei)
This trial will enroll 47 subjects who will be be treated with the IBA PROTEUS® PLUS Proton Beam radiation Therapy (PBT) medical device.
- Trial name
- NCT07137195
- Testing
- Proton Beam Therapy (PBT)
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Ion Beam Applications
Gastroesophageal Reflux
ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)
The purpose of this study is to evaluate the effect of ADX10059 in patients with gastroesophageal reflux disease who are partial responders to proton pump inhibitors
- Trial name
- NCT00810485
- Testing
- ADX10059
- Where
- 40 sites in United States, France and 3 more
- Volunteers
- 298 people
- Sponsor
- Addex Pharma S.A.
Gastroesophageal Reflux Disease, GERD
What is the Predictive Value of the Reflux Impact Scale
Gastric distress is a common phenomenon in our society. Heartburn and regurgitation occur daily in about 7% of the adult population,weekly 14-20% pf the adults and monthly in 34-44% of adults.
- Conditions
- Gastroesophageal Reflux Disease, GERD, Heartburn, Acid Regurgitation
- Trial name
- PREDICT (NCT00536328)
- Volunteers
- 938 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)
The purpose of this study is to assess how patients with gastro-oesophageal reflux disease (heartburn) who are currently receiving treatment with a proton pump inhibitor but are still experiencing symptoms will benefit from a…
- Trial name
- NEON (NCT00734097)
- Testing
- Esomeprazole 40 mg, Physical Exam, Quality of Life Questionnaires
- Where
- 10 sites in Argentina, Chile and 2 more
- Volunteers
- 314 people
- Sponsor
- AstraZeneca
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of a New Spray Dried Dispersion (SDD) Formulation of CC-11050 After Single Dose of CC-11050 and to Evaluate the Pharmacokinetics of CC-11050 Under Fasted and Fed Conditions and After Coadministration With Omeprazole
This is a two-part study to be conducted at single study center, (additional center(s) may be selected if needed) to assess the safety, tolerability, PK and PD parameters for a new SDD formulation of CC-11050 in healthy subjects.
- Trial name
- NCT04139226
- Testing
- CC-11050
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Amgen
Gastroesophageal Reflux
Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI)
The purpose of this study is to determine the effect of vonoprazan compared to esomeprazole for preventing heartburn symptoms over a 4-week treatment period in participants who have a partial response to treatment with…
- Trial name
- NCT02743949
- Testing
- Vonoprazan, Esomeprazole
- Where
- 39 sites in Belgium, Bulgaria and 4 more
- Volunteers
- 256 people
- Sponsor
- Takeda
Helicobacter Infections, Bacterial Infections
Study of the Safety and Effectiveness of Rabeprazole in Treatment of Helicobacter Pylori Infection in Adults.
The purpose of the study is to confirm the safety and effectiveness of rabeprazole in the treatment of adult patients with Helicobacter pylori (H. pylori) infection in routine clinical practice.
- Trial name
- NCT00216450
- Testing
- rabeprazole sodium
- Volunteers
- 80 people
- Sponsor
- Janssen Cilag Pharmaceutica S.A.C.I., Greece
Gastroesophageal Reflux, Heartburn
A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD)
The purpose of the study is to confirm the safety and effectiveness of rabeprazole in the treatment of patients with erosive or ulcerative gastroesophageal reflux disease (GERD) in routine primary health care.
- Trial name
- NCT00216489
- Testing
- rabeprazole sodium
- Volunteers
- 191 people
- Sponsor
- Janssen Cilag Pharmaceutica S.A.C.I., Greece
Heartburn
Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn
Heartburn, a burning sensation in the chest or throat, occurs in many patients when acidic stomach contents move into the esophagus from the stomach.
- Trial name
- NCT00389948
- Testing
- Lanzoprazole
- Where
- 28 sites in United States
- Volunteers
- 576 people
- Sponsor
- Novartis
Patients With Typical Symptoms of GERD (GERD Q >= 8)
Proton Pump Inhibitor Empirical Treatment in Management of Outpatients With Gastroesophageal Reflux Disease.
China Survey of Proton Pump Inhibitor Empirical Treatment in Management of Outpatients with Gastroesophageal Reflux Disease
- Trial name
- NCT02606851
- Where
- 10 sites in China
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
Efficacy And Safety Of PF-00885706 For The Relief Of Symptoms In Subjects With Gastro-esophageal Reflux Disease (GERD)
To understand the dose-response characteristics of PF-00885706 for efficacy in terms of symptomatic relief when used as add-on treatment to esomeprazole 20mg (standard proton pump inhibitor [PPI] treatment), in subjects with…
- Trial name
- NCT00730665
- Testing
- PF-00885706, Esomeprazole
- Where
- 38 sites in Belgium, Brazil and 5 more
- Volunteers
- 81 people
- Sponsor
- Pfizer
Gastroesophageal Reflux, Heartburn
A Study of Efficacy and Safety of "On-demand" Maintenance Therapy With Rabeprazole in Patients With Non-erosive Reflux Disease (NERD)
The purpose of this study is to assess the efficacy and safety of long-term, "on-demand" maintenance therapy with rabeprazole in patients with non-erosive reflux disease (NERD).
- Trial name
- NCT00236392
- Testing
- rabeprazole
- Volunteers
- 422 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Heartburn
Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn
Heartburn, a burning sensation in the chest or throat, occurs in many patients when acidic stomach contents move into the esophagus from the stomach.
- Trial name
- NCT00390390
- Testing
- Lansoprazole
- Where
- 30 sites in United States
- Volunteers
- 576 people
- Sponsor
- Novartis
GERD, Acid Reflux Disease
Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms
This research study is being done to gather information about how to do further clinical studies using AZD3355 as an add-on treatment to proton pump inhibitors (PPI).
- Conditions
- GERD, Acid Reflux Disease, Heartburn, Regurgitation
- Trial name
- C27 (NCT00703534)
- Testing
- AZD3355, Gelusil®
- Where
- 84 sites in United States
- Volunteers
- 478 people
- Sponsor
- AstraZeneca
Healthy
Pharmacokinetics of Dipyridamole Administered as Aggrenox® (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pH
Comparison of pharmacokinetics of dipyridamole administered as Aggrenox versus dipyridamole administered as the immediate release formulation plus aspirin, under conditions of reduced stomach acidity.
- Trial name
- NCT02251184
- Testing
- Aggrenox, Dipyridamole, Aspirin
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin
Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)
The primary objective of this study to examine the long-term safety of rabeprazole 5 mg or 10 mg tablets administered once daily in participants who were confirmed to have no recurrence of gastric or duodenal ulcer by endoscopic…
- Trial name
- NCT01398410
- Testing
- Rabeprazole
- Where
- 50 sites in Japan
- Volunteers
- 405 people
- Sponsor
- Eisai Co., Ltd.
Osteoarthritis, Rheumatoid Arthritis
Assessment of NSAID-treated Patients Adherence to Co-prescribed Proton Pump Inhibitor (PPI)
The primary objective of this cross-sectional observational real life study is to investigate the patient reported adherence to PPI, when prescribed as prevention of NSAID associated GI Ulcers to patients prescribed a NSAID.
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- CONVOY (NCT01519375)
- Where
- 8 sites in Sweden
- Volunteers
- 102 people
- Sponsor
- AstraZeneca
Frequent Heartburn
Efficacy/Safety of Lansoprazole in Patients With Frequent Nighttime Heartburn
Heartburn, a burning sensation in the chest or throat, occurs in many individuals when acidic stomach contents move upward into the esophagus from the stomach.
- Trial name
- NCT00701259
- Testing
- Lansoprazole
- Where
- United States
- Volunteers
- 852 people
- Sponsor
- Novartis